A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

This study is a multicentre, randomised, parallel-controlled, open-label, 3 phase clinical trial. The subjects were untreated, unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma with low PD-L1 expression. Patients were randomly assigned to receive chemoradiation or chemotherapy in combination with Tislelizumab at a ratio of 1: 1. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. We hypothesized that in advanced esophageal squamous cell carcinoma patients with low PD-L1 expression, chemoradiation versus chemothe

Trial Details

NCT ID
NCT05919030
Phase
PHASE3
Sponsor
Renmin Hospital of Wuhan University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Intensity-modulated radiotherapy (IMRT)
  • Tislelizumab
  • Cisplatin
  • Nab paclitaxel
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Subjects must have histologically confirmed squamous cell carcinoma of esophagus (per AJCC 8th edition).
  • Subjects must have unresectable advanced, recurrent or metastatic ESCC.
  • Subjects must not be amenable to curative approaches such as definitive chemoradiation and/or surgery.
  • PD-L1 expression (CPS) is less than 10.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →